Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and sales milestones.
Cytiva-Cell & Gene Therapy WP 2
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
GEMMABio raises $34m to advance gene therapy programmes
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
Intellia’s gene editing therapy shows early potential in rare heart condition
bit.bio defends European patent for ‘novel’ opti-ox technology
Purespring secures $105m to start Phase I/II trial of IgAN gene therapy
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
